Stephen D Skaper

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro
    Stephen D Skaper
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, United Kingdom
    Glia 54:234-42. 2006
  2. ncbi request reprint Neuronal growth-promoting and inhibitory cues in neuroprotection and neuroregeneration
    Stephen D Skaper
    Department of Neuro Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
    Ann N Y Acad Sci 1053:376-85. 2005
  3. ncbi request reprint The brain as a target for inflammatory processes and neuroprotective strategies
    Stephen D Skaper
    Neurodegeneration Research Department, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, Essex CM19 5 AW, United Kingdom
    Ann N Y Acad Sci 1122:23-34. 2007
  4. ncbi request reprint The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors
    Stephen D Skaper
    Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, CM19 5AW, Harlow, Essex, UK
    CNS Neurol Disord Drug Targets 7:46-62. 2008
  5. ncbi request reprint MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease
    Ainsley A Culbert
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, United Kingdom
    J Biol Chem 281:23658-67. 2006
  6. ncbi request reprint Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms
    Claudia Rosin
    Neuro Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, Essex, UK
    J Neurochem 90:1173-85. 2004
  7. ncbi request reprint MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures
    Davide Franceschini
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, UK
    Eur J Pharmacol 553:18-27. 2006
  8. doi request reprint Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis
    Nicholas A Evans
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Essex, United Kingdom
    J Neurosci Methods 175:96-103. 2008
  9. ncbi request reprint TRPM2 is elevated in the tMCAO stroke model, transcriptionally regulated, and functionally expressed in C13 microglia
    Elena Fonfria
    Neurology and GI CEDD, GlaxoSmithKline, Harlow, UK
    J Recept Signal Transduct Res 26:179-98. 2006
  10. ncbi request reprint Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity
    Laura Facci
    Neurophysiology and Cell Sciences, GlaxoSmithKline Research and Development Ltd, Third Avenue, Harlow, Essex CM19 5AW, UK
    Neuroreport 14:1467-70. 2003

Collaborators

Detail Information

Publications25

  1. ncbi request reprint P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro
    Stephen D Skaper
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, United Kingdom
    Glia 54:234-42. 2006
    ....
  2. ncbi request reprint Neuronal growth-promoting and inhibitory cues in neuroprotection and neuroregeneration
    Stephen D Skaper
    Department of Neuro Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
    Ann N Y Acad Sci 1053:376-85. 2005
    ....
  3. ncbi request reprint The brain as a target for inflammatory processes and neuroprotective strategies
    Stephen D Skaper
    Neurodegeneration Research Department, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, Essex CM19 5 AW, United Kingdom
    Ann N Y Acad Sci 1122:23-34. 2007
    ....
  4. ncbi request reprint The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors
    Stephen D Skaper
    Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, CM19 5AW, Harlow, Essex, UK
    CNS Neurol Disord Drug Targets 7:46-62. 2008
    ..Moreover, exciting recent data describing G-protein-coupled receptor transactivation of Trk receptors and their downstream signalling pathways raise the possibility of using small molecules to elicit neuroprotective effects...
  5. ncbi request reprint MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease
    Ainsley A Culbert
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, United Kingdom
    J Biol Chem 281:23658-67. 2006
    ..Our data propose a role for MK2 in AD brain pathology, for which neuroinflammation involving cytokines and chemokines and overt neuronal loss have been documented...
  6. ncbi request reprint Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms
    Claudia Rosin
    Neuro Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, Essex, UK
    J Neurochem 90:1173-85. 2004
    ..Glutamate toxicity may conceivably be operative in neuropathological conditions that disrupt neuronal/oligodendrocyte interactions in axons, e.g. multiple sclerosis and ischaemia-reperfusion injury...
  7. ncbi request reprint MEK inhibition exacerbates ischemic calcium imbalance and neuronal cell death in rat cortical cultures
    Davide Franceschini
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, UK
    Eur J Pharmacol 553:18-27. 2006
    ..These data suggest that in this ischemic model the MAPK/ERK pathway might exert a regulatory effect on calcium entry independent from gene expression...
  8. doi request reprint Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis
    Nicholas A Evans
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Essex, United Kingdom
    J Neurosci Methods 175:96-103. 2008
    ..These effects of Abeta(1-42) on synapse number and neurite outgrowth are similar to those described within AD patient pathology and transgenic mouse models...
  9. ncbi request reprint TRPM2 is elevated in the tMCAO stroke model, transcriptionally regulated, and functionally expressed in C13 microglia
    Elena Fonfria
    Neurology and GI CEDD, GlaxoSmithKline, Harlow, UK
    J Recept Signal Transduct Res 26:179-98. 2006
    ..Activation of TRPM2 in microglia during ischemic brain injury may mediate key aspects of microglial pathophysiological responses...
  10. ncbi request reprint Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity
    Laura Facci
    Neurophysiology and Cell Sciences, GlaxoSmithKline Research and Development Ltd, Third Avenue, Harlow, Essex CM19 5AW, UK
    Neuroreport 14:1467-70. 2003
    ..As GSK-3 can modulate transcriptional events, these results may provide insight into the identification of new neuroprotective targets...
  11. ncbi request reprint Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?
    Elaine A Irving
    Neurology and GI CEDD, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Harlow, Essex, UK
    J Cereb Blood Flow Metab 25:98-107. 2005
    ..Together, these data highlight the potential for the use of anti-MAG antibodies as therapeutic agents for the treatment of stroke...
  12. doi request reprint Apoptosis-associated tyrosine kinase and neuronal cell death
    Jane P Hughes
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Harlow, UK
    Neurochem Res 35:588-97. 2010
    ..Moreover, CGN cultured from AATYK-deficient mice remained sensitive to death in K5 medium. Thus, AATYK activation may not be a physiologically relevant principal regulatory target of the GSK-3 death pathway in KCl-deprived CGN...
  13. ncbi request reprint Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation
    Claudia Rosin
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, United Kingdom
    Glia 52:336-43. 2005
    ..Our results suggest that dopamine D2 and D3 receptor activation may play an important role in oligodendrocyte protection against oxidative glutamate toxicity and oxygen-glucose deprivation injury...
  14. doi request reprint Oligodendrocytes are a novel source of amyloid peptide generation
    Stephen D Skaper
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    Neurochem Res 34:2243-50. 2009
    ..Disturbances of APP processing and/ or synthesis in oligodendrocytes may account for some myelin disorders observed in Alzheimer's disease and other senile dementias...
  15. ncbi request reprint A dimeric version of the short N-cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-cadherin/fibroblast growth factor receptor signalling cascade
    Stephen D Skaper
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Harlow CM19 5AW, Essex, UK
    Mol Cell Neurosci 26:17-23. 2004
    ....
  16. doi request reprint TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h
    Ishrut Hussain
    Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Ltd, Harlow, UK
    Neurodegener Dis 8:15-24. 2011
    ..Therefore, efforts have focussed on the modulation of γ-secretase activity to selectively decrease levels of Aβ₄₂ peptide while avoiding deleterious activity on Notch processing...
  17. ncbi request reprint The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, GlaxoSmithKline, PO Box 1539, Mail Code UW 2523, 709 Swedeland Road, 19406, King of Prussia, PA, USA
    Eur J Pharmacol 447:37-42. 2002
    ....
  18. pmc TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase
    Elena Fonfria
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW
    Br J Pharmacol 143:186-92. 2004
    ..64+/-0.38; 6.68+/-0.28; 4.78+/-0.05, respectively). 6. These data suggest that oxidative stress causes TRPM2 channel opening in both recombinant and endogenously expressing cell systems via activation of PARP enzymes...
  19. ncbi request reprint Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells
    Sonia Marco
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, CM19 5AW Harlow, Essex, United Kingdom
    Neurosci Lett 401:219-24. 2006
    ..These data suggest that Abeta1-42 effects on tight junction protein complexes may alter blood-brain barrier integrity and contribute to the neuropathological sequelae of Alzheimer's disease...
  20. ncbi request reprint Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection
    Stephen D Skaper
    Department of Neurophysiology and Cell Sciences, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, Harlow, United Kingdom
    Ann N Y Acad Sci 993:217-28; discussion 287-8. 2003
    ..The hypothesis that PARPs might regulate cell fate as essential modulators of death and survival transcriptional programs is discussed with relation to nuclear factor kappaB and p53...
  21. ncbi request reprint Mitogen and stress response kinase-1 (MSK1) mediates excitotoxic induced death of hippocampal neurones
    Jane P Hughes
    Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK
    J Neurochem 86:25-32. 2003
    ..Together, these data indicate that MSK1 is a physiological kinase for CREB and that this activity is an essential component of activity-dependent neuronal cell death...
  22. ncbi request reprint Signalling pathways with small molecule mimetics and modulators to achieve neuroprotection and regeneration
    Stephen D Skaper
    CNS Neurol Disord Drug Targets 7:45. 2008
  23. ncbi request reprint A novel somatodendritic marker defined by a peptide derived from the ALS2 protein
    Virginie Bros
    Department of Neurology, Institute of Psychiatry, King s College London, De Crespigny Park, London SE5 8AF
    Neuroreport 15:2155-9. 2004
    ..ARDA was also selectively localized to the somatodendritic compartment of motor neurons in human spinal cord. The ARDA antigen therefore represents a novel somatodendritic marker for embryonic and adult neurons...
  24. doi request reprint Generation of a alpha-synuclein-based rat model of Parkinson's disease
    Alessandra Recchia
    Department of Pharmacology and Anesthesiology, University of Padua, Largo Meneghetti, 2, 35131 Padua, Italy
    Neurobiol Dis 30:8-18. 2008
    ....
  25. ncbi request reprint Alpha-synuclein and Parkinson's disease
    Alessandra Recchia
    Department of Pharmacology and Anesthesiology, University of Padova, 35131 Padova, Italy
    FASEB J 18:617-26. 2004
    ..The available animal models of PD, each present distinct advantages and limits. Findings to date suggest that alpha-syn-based models represent a paradigm, which is closest to the human pathology...